Tvardi Therapeutics plunges after lung disease drug fails to meet trial goals

Tvardi Therapeutics

13/10/2025 15:57

Updates

** Shares of drug developer Tvardi Therapeutics TVRD.O fall as much as 84.8% to a record low of $5.65

** Stock is set for its worst day ever, if losses hold

** Company says its experimental drug, TTI-101, failed to meet goals in a mid-stage trial on patients with a type of lung disease called idiopathic pulmonary fibrosis

** The 88-patient trial evaluated TTI-101 as a standalone treatment or in combination with Germany-based Boehringer Ingelheim's nintedanib

** Nintedanib is FDA-approved to slow lung function decline in IPF

** Discontinuation rates were high in treatment arms — 56.7% for the 400 mg dose and 62.1% for 800 mg dose vs 10.3% in placebo

** Most discontinuations were due to gastrointestinal side effects, especially with nintedanib - TVRD

** It adds early results showed lung function improvements on the drug were similar to placebo

** Raymond James says it's unclear why the placebo group had such a small drop in lung function, but the decline was much lower than seen in similar studies

** Including session moves, stock down 65.7% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))